Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01364415
Recruitment Status : Completed
First Posted : June 2, 2011
Last Update Posted : June 28, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : April 2016
  Study Completion Date : April 2016